Free Access
Med Sci (Paris)
Volume 22, Number 4, Avril 2006
Page(s) 405 - 410
Section M/S revues
Published online 15 April 2006
  1. Feldmann H, Wahl-Jensen V, Jones SM, Stroher U. Ebola virus ecology : a continuing mystery. Trends Microbiol 2004; 12 : 433–7. [Google Scholar]
  2. Leroy EM, Rouquet P, Formenty P, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004; 303 : 387–90. [Google Scholar]
  3. Rouquet P, Froment JM, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005; 11 : 283–90. [Google Scholar]
  4. Baize S. A single shot against Ebola and Marburg virus. Nat Med 2005; 11 : 720–1. [Google Scholar]
  5. Chandran K, Sullivan NJ, Felbor U, et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308 : 1643–5. [Google Scholar]
  6. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11 : 786–90. [Google Scholar]
  7. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998; 95 : 5762–7. [Google Scholar]
  8. Volchkov VE, Becker S, Volchkova VA, et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995; 214 : 421–30. [Google Scholar]
  9. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA : RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291 : 1965–9. [Google Scholar]
  10. Dutch RE, Jardetzky TS, Lamb RA. Virus membrane fusion proteins : biological machines that undergo a metamorphosis. Biosci Rep 2000; 20 : 597–612. [Google Scholar]
  11. Weissenhorn W, Dessen A, LJ Calder, et al. Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 1999; 16 : 3–9. [Google Scholar]
  12. Takada A, Robison C, Goto H, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 1997; 94 : 14764–9. [Google Scholar]
  13. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses : identification of receptor-deficient cell lines. J Virol 1998; 72 : 3155–60. [Google Scholar]
  14. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78 : 5458–65. [Google Scholar]
  15. Feldmann H, Jones SM, Schnittler HJ, Geisbert T. Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 2005; 6 : 823–30. [Google Scholar]
  16. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5 : 423–6. [Google Scholar]
  17. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128 : 163–8. [Google Scholar]
  18. Grolla A, Lucht A, Dick D, et al. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot 2005; 98 : 205–9. [Google Scholar]
  19. Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lancet 1980; 2 : 1294–5. [Google Scholar]
  20. Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8 : 503–7. [Google Scholar]
  21. Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251 : 28–37. [Google Scholar]
  22. Gilligan JK, Geisbert JB, Jahrling PB, Anderson K. Assessment of protective immunity conferred by recombinant VACV to guinea pigs challenged with Ebola virus. In : Brown F, Burton D, Doherty P, et al., edS. Vaccines. Cold Spring Harbor (NY) : Cold Spring Harbor Laboratory Press, 1997 : 87–92. [Google Scholar]
  23. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100 : 15889–94. [Google Scholar]
  24. Warfield KL, Swenson DL, Negley DL, et al. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22 : 3495–502. [Google Scholar]
  25. Swenson DL, Warfield KL, Negley DL, et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23 : 3033–42. [Google Scholar]
  26. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246 : 134–44. [Google Scholar]
  27. Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998; 4 : 37–42. [Google Scholar]
  28. Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408 : 605–9. [Google Scholar]
  29. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346 : 394–401. [Google Scholar]
  30. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424 : 681–4. [Google Scholar]
  31. McKenna PM, McGettigan JP, Pomerantz RJ, et al. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 2003; 1 : 229–37. [Google Scholar]
  32. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 2 : e183. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.